Charles River Laboratories (CRL) Tops Q3 EPS by 8c; Narrows Outlook
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $181.56 -1.86%
EPS Growth %: -12.5%
Financial Fact:
Continuing operations (in dollars per share): 0.79
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: -12.5%
Financial Fact:
Continuing operations (in dollars per share): 0.79
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q3 EPS of $1.30, $0.08 better than the analyst estimate of $1.22. Revenue for the quarter came in at $464.2 million versus the consensus estimate of $458.72 million.
GUIDANCE:
Charles River Laboratories sees FY2017 EPS of $5.08-$5.18, versus prior $5.00-$5.15 and the consensus of $5.10.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Pfizer lung cancer drug misses survival goal in Phase 3 trial
- C.H. Robinson acquires DeSpir Logistics for $75 million
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
